<DOC>
	<DOC>NCT00602134</DOC>
	<brief_summary>The objective of this study was to assess the bioequivalence of a potential generic 6-mercaptopurine 50 mg tablet formulation compared with GlaxoSmithKline PurinetholÂ® (mercaptopurine) 50-mg scored tablets following a single 50 mg oral dose administered in the fasted state.</brief_summary>
	<brief_title>Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>No clinically significant abnormal findings on physical examination, medical history, or clinical laboratory results. Must voluntarily consent. Must not have a known history of thiopurine methyltransferase deficiency or family history. Must not have a history of elevated uric acid or gout. Must not be currently using allopurinol.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>